U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:U.S. Stem Cell Inc (USRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10098
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company’s lead product MyoCell, is designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem Cell is headquartered in Sunrise, Florida, the US.

U.S. Stem Cell Inc (USRM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
Private Equity 13
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Partnerships 14
Bioheart Forms Joint Venture with Walter Bell 14
Licensing Agreements 15
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
Debt Offering 18
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Acquisition 28
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc – Key Competitors 30
U.S. Stem Cell Inc – Key Employees 31
U.S. Stem Cell Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: USRM posts 25% nine month revenue increase from 3Q 2017 33
Aug 08, 2018: USRM posts profitable results for second quarter 2018 34
May 09, 2018: U.S. Stem Cell Reports First Quarter Results 35
Apr 16, 2018: USRM Reports 2017 Financial Results 36
Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company’s History 37
Corporate Communications 38
Sep 11, 2018: USRM hires senior VP of US & international sales 38
Legal and Regulatory 39
Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 39
Product News 40
Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 40
Other Significant Developments 42
Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 42
Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 43
Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Bioheart Forms Joint Venture with Walter Bell 14
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc, Key Competitors 30
U.S. Stem Cell Inc, Key Employees 31
U.S. Stem Cell Inc, Joint Venture 32

List of Figures
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Greenply Industries Ltd:企業の戦略・SWOT・財務情報
    Greenply Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Greenply Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Origin Energy Limited:企業の戦略・SWOT・財務分析
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Carr’s Group Plc (CARR):企業の財務・戦略的SWOT分析
    Carr's Group Plc (CARR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Accelya Solutions India Ltd (ACCELYA):企業の財務・戦略的SWOT分析
    Accelya Solutions India Ltd (ACCELYA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • DIAsource ImmunoAssays SA:企業の製品パイプライン分析2018
    Summary DIAsource ImmunoAssays SA (DIAsource), formerly BioSource Europe SA, a subsidiary of BioVendor - Laboratorni Medicina as, is a diagnostics company that develops, manufactures and markets clinical diagnostic products. The company’s products comprise immunoassays, antibodies, instruments and R …
  • Ego Pharmaceuticals Pty Ltd:企業の戦略的SWOT分析
    Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • BlueWillow Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BlueWillow Biologics Inc (BlueWillow), formerly NanoBio Corp is a biopharmaceutical company that develops intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company’s pipeline products include anthrax, H5 influenza, pertussis, RSV, HSV-2, and s …
  • Radiation Monitoring Devices Inc:企業の製品パイプライン分析2018
    Summary Radiation Monitoring Devices Inc (RMD), a subsidiary of Dynasil Corporation of America, is a research and development company that provides solutions for security, medical and industrial applications. The company’s products include scintillators, APDs, cesium iodide, solid state photomultipl …
  • Nexstim Plc (NXTMH):企業の財務・戦略的SWOT分析
    Nexstim Plc (NXTMH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OsteoVantage Inc:製品パイプライン分析
    Summary OsteoVantage Inc (OsteoVantage) is a medical device company that develops osteogenic spinal instrumentation technology used in spinal fusion procedures. The company’s INDOS system is an osteogenic spinal instrumentation for use in lumbar spinal fusion procedures. It also offers osteomodulati …
  • Lohmann & Rauscher GmbH & Co. KG:企業の戦略的SWOT分析
    Lohmann & Rauscher GmbH & Co. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • PSR Group BV-製薬・医療分野:企業M&A・提携分析
    Summary PSR Group BV (PSR) is a contract research organization and staffing consultancy that operates through two divisions, namely, PSR Orphan Experts and PSR Pharma Resource. The company’s PSR Orphan Experts is a contract research organization that concentrates on orphan drug development. It provi …
  • Beactica AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Beactica AB (Beactica) is a drug discovery company develops a pipeline of novel and mechanistically defined small molecule therapeutics. The company offers wide range of services such as fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate ana …
  • OMV New Zealand Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary OMV New Zealand Ltd (OMV NZ) a subsidiary of OMV AG, is an oil and natural gas exploration and production company. It offers upstream production services with offshore oil and gas fields in Maari, Pohokura, and Maui across Taranaki coast, Tunisia and in the Black Sea. The company operates ex …
  • SREI Infrastructure Finance Ltd:企業のM&A・事業提携・投資動向
    SREI Infrastructure Finance Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SREI Infrastructure Finance Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Abionic SA-医療機器分野:企業M&A・提携分析
    Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company offers products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE application for android, iPhone & iPad, and accessories. Its abioSCOPE in vitro tests are design …
  • C&A:企業の戦略・SWOT・財務情報
    C&A - Strategy, SWOT and Corporate Finance Report Summary C&A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Rothschild Bank Ag
    Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Coslight Technology International Group Ltd (1043):企業の財務・戦略的SWOT分析
    Coslight Technology International Group Ltd (1043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Getinge AB (GETI B):企業の財務・戦略的SWOT分析
    Getinge AB (GETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆